Literature DB >> 12947345

Amelioration of cyclosporin A effect on microvasculature by endothelin inhibitor.

Chumpon Wilasrusmee1, Phil Ondocin, David Bruch, Gaurang Shah, Smita Kittur, Skuntala Wilasrusmee, Dilip S Kittur.   

Abstract

BACKGROUND: We have previously shown that endothelial injury by cyclosporin A (CyA) is associated with an increased endothelin-1 (ET-1) release. We now sought to determine, in an animal model of angiogenesis, if inhibiting the effect of ET-1 on endothelial cells (ECs) would reverse the CyA-mediated endothelial injury in an animal model of angiogenesis.
METHODS: An angiogenic mixture of Matrigel (0.5 ml), fibroblast growth factor (1 ng/ml), vascular endothelial growth factor (100 ng/ml), and heparin (64 unit/ml) was injected as a subcutaneous plug in the flank of C3H mice (n = 5). In experimental groups CyA (20 mg/ml), CyA, and BQ 123 (ET-A receptor antagonist), CyA and PD 142893 (ET-A and ET-B receptor antagonist), or CyA and ET-1 antibody were added to the angiogenic mixture. Angiogenesis in the mixture was quantified by modified planimetric point counting method in skin/Matrigel cross-sections stained with factor VIII to highlight endothelial neocapillaries. Mean +/- SD of angiogenic area was analyzed with analysis of variance and Bonferroni test. The survival curves obtained by Kaplan-Meier analysis were compared between the groups, and the statistical significance of survival and mortality rates was computed by log rank's and Fisher's exact test, respectively.
RESULTS: The mean +/- SD of angiogenic area in control animals (without CyA in the angiogenic mixture) was 56.76 +/- 4.2. CyA inhibited angiogenesis in the subcutaneous angiogenic plug. Adding CyA to the angiogenic mixture significantly reduced angiogenic area (5.33 +/- 1.4, P <.001) while vehicle for CyA had no such effect (56.33 +/- 3.8, P =.10). Polyclonal ET-1 antibody or PD 142893 ameliorated the effect of CyA, whereas BQ 123 did not. The mean angiogenic areas in animals with ET-1 antibody, PD 142893, or BQ 123 in the angiogenic mixture were 57.20 +/- 7.5 (P =.06), 46.00 +/- 11.5 (P = 1.0), 8.60 +/- 2.9 (P <.001), respectively.
CONCLUSIONS: Our data show that blocking ET-B receptors specifically ameliorates the microvascular injury to the neocapillaries in angiogenesis caused by CyA. Antiendothelin-1 antibody and ETR antagonist (PD 142893) could, therefore, reduce the ill effects of CyA on microvascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947345     DOI: 10.1067/msy.2003.233

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1.

Authors:  Neil J Davie; Evgenia V Gerasimovskaya; Stephen E Hofmeister; Aaron P Richman; Peter L Jones; John T Reeves; Kurt R Stenmark
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.

Authors:  Mark LaSpina; Sudipta Tripathi; Louis A Gatto; David Bruch; Kristopher G Maier; Dilip S Kittur
Journal:  J Surg Res       Date:  2008-01-29       Impact factor: 2.192

Review 3.  The adventitia: essential regulator of vascular wall structure and function.

Authors:  Kurt R Stenmark; Michael E Yeager; Karim C El Kasmi; Eva Nozik-Grayck; Evgenia V Gerasimovskaya; Min Li; Suzette R Riddle; Maria G Frid
Journal:  Annu Rev Physiol       Date:  2012-12-03       Impact factor: 19.318

Review 4.  The adventitia: Essential role in pulmonary vascular remodeling.

Authors:  Kurt R Stenmark; Eva Nozik-Grayck; Evgenia Gerasimovskaya; Adil Anwar; Min Li; Suzette Riddle; Maria Frid
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

5.  Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change.

Authors:  Kurt R Stenmark; Maria G Frid; Michael Yeager; Min Li; Suzette Riddle; Timothy McKinsey; Karim C El Kasmi
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.